Molbio Diagnostics IPO Allotment Status

Molbio Diagnostics IPO is a book-built issue aiming to raise ₹939.70 crore. The issue comprises a fresh issue of equity shares worth up to ₹200 crore and an offer for sale of up to 91.66 lakh equity shares aggregating to approximately ₹739.70 crore.  

The bidding window was open from August 10, 2026, to August 12, 2026, while the basis of allotment is scheduled to be finalised on August 13, 2026. Molbio Diagnostics is expected to list on the BSE and NSE on August 17, 2026. 

As of the latest available update, the allotment status is expected to be released after the basis of allotment is finalised. Investors can check their application status through the official registrar, KFin Technologies, or through the BSE and NSE websites. 

The IPO was priced at ₹768–₹807 per share with a lot size of 18 shares. The issue received bids for approximately 57.32 crore equity shares against 81.59 lakh shares on offer, resulting in an overall subscription of 70.26 times. Qualified Institutional Buyers subscribed 186.39 times, Non-Institutional Investors subscribed 49.80 times and Retail Individual Investors subscribed 12.96 times. 

How to Check Molbio Diagnostics IPO Allotment Status Online on NSE? 

• Go to the NSE IPO bid verification and application status page.
• Select the option for IPO bids or application status.
• Choose “Molbio Diagnostics” from the issue name dropdown.
• Enter your Application Number or PAN.
• Complete the verification, if prompted.
• Click on Submit to view your application and allotment status. 

How to Check Molbio Diagnostics IPO Allotment Status Online on BSE? 

• Visit the BSE IPO application status page.
• Select “Equity” under the Issue Type.
• Choose “Molbio Diagnostics” from the Issue Name dropdown.
• Enter your Application Number or PAN.
• Complete the captcha verification.
• Click on Submit to check the allotment status. 

How to Check Molbio Diagnostics IPO Allotment Status Online on the Registrar’s Website? 

• Visit the official KFin Technologies IPO allotment website.
• Select “Molbio Diagnostics” or “Molbio Diagnostics Limited” from the list of available issues.
• Choose whether you want to check the status using your PAN, Application Number or DP ID/Client ID.
• Enter the required details.
• Complete the captcha verification.
• Click on Submit to view your allotment status. 

Molbio Diagnostics IPO Details 

Molbio Diagnostics’ ₹939.70 crore IPO was priced in the range of ₹768–₹807 per share. The issue includes a fresh issue worth ₹200 crore and an offer for sale of up to 91.66 lakh equity shares worth approximately ₹739.70 crore. Proceeds from the fresh issue will go to the company, while the OFS proceeds will be received by the selling shareholders. 

The subscription period began on August 10, 2026, and closed on August 12, 2026. The basis of allotment is scheduled to be finalised on August 13, 2026. Refunds and demat account credits are expected on August 14, 2026, while the shares are scheduled to be listed on the BSE and NSE on August 17, 2026. 

With a lot size of 18 equity shares, retail investors were required to invest a minimum of ₹14,526 at the upper price band of ₹807 per share. 

Allocation Quota for Molbio Diagnostics IPO 

The table below provides the category-wise allocation of shares in the Molbio Diagnostics IPO. 

Data Source: IPO offer details. 

Molbio Diagnostics IPO – Overall Subscription Status 

Note: The subscription figures are based on data available after the issue closed on August 12, 2026. 

Molbio Diagnostics IPO Business Overview 

Incorporated in 2000, Molbio Diagnostics Limited is a Goa-headquartered molecular diagnostics company focused on point-of-care testing. The company operates through its proprietary Truenat platform, a portable, battery-operated real-time polymerase chain reaction system designed to support molecular testing closer to the point of care. 

The Truenat platform is intended to enable diagnostic testing in decentralised healthcare settings, including locations where conventional laboratory infrastructure may be limited. Molbio’s product portfolio includes testing solutions for infectious diseases and other diagnostic applications. 

The company plans to use a portion of the fresh issue proceeds to fund capital expenditure for a research and development facility, a Centre of Excellence and connected office space. These facilities are expected to be operated partly through its wholly owned subsidiary, Bigtec Private Limited. 

Molbio Diagnostics also intends to use the fresh issue proceeds to purchase plant, machinery and other equipment for its manufacturing units in Goa and Visakhapatnam. The remaining proceeds will be used for general corporate purposes. 

Know more about IPO allotment status and check your application details online for the latest updates on share allocation. 

Disclaimer: This article has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute personal investment advice or a recommendation to buy, sell or hold any security. Investors should conduct their own research and consult a SEBI-registered investment adviser before making investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.